• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

In vitro immunomodulatory activity of celastrol against influenza A virus infection

tetano

Editor, Senior Moderator
Immunopharmacol Immunotoxicol. 2018 Mar 1:1-6. doi: 10.1080/08923973.2018.1440591. [Epub ahead of print]
[h=1]In vitro immunomodulatory activity of celastrol against influenza A virus infection.[/h] Khalili N[SUP]1[/SUP], Karimi A[SUP]2[/SUP], Moradi MT[SUP]2[/SUP], Shirzad H[SUP]3[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]CONTEXT:[/h] The influenza A virus (IAV) causes severe respiratory disease that remains a leading reason for morbidity and mortality. Previous studies have indicated that influenza complications in addition to viral replication are due to overproduction of pro-inflammatory cytokines. Therefore, a new compound is needed to be used with current antiviral drugs to modulate overproduction of pro-inflammatory cytokines in IAV infection.
[h=4]OBJECTIVE:[/h] This study investigated the effect of celastrol on mRNA expression and concentration levels of the pro-inflammatory cytokines tumor necrosis factor alpha (TNFα) and interleukin-6 (IL6) that are induced by influenza A/Puerto Rico/8/34 (H1N1; PR8) in Madin-Darby Canine Kidney (MDCK) cells. The effect of this compound on virus titration and viral mRNA expression was also investigated.
[h=4]METHODS:[/h] Confluent MDCK cells were infected with influenza virus (H1N1; PR8) and treated with celastrol at different concentrations. After incubation, mRNA expression and concentrations of TNFα and IL6 were investigated using real-time polymerase chain reaction (PCR) and ELISA. The viral mRNA expression and virus titration were investigated using real-time PCR and 50% tissue culture infectious dose (TCID[SUB]50[/SUB]) assay, respectively.
[h=4]RESULTS:[/h] mRNA expression and concentrations of TNFα and IL6 increased significantly in control virus compared to cell control, and decreased significantly when compared with control virus after celastrol treatment. Viral mRNA expression and virus titration did not decrease after celastrol treatment.
[h=4]CONCLUSION:[/h] Due to reducing mRNA expression and concentrations of TNFα and IL6, celastrol can serve as a suitable choice to control cytokine-induced inflammation in IAV infection, and therefore it can be used with current antiviral drugs.


[h=4]KEYWORDS:[/h] Influenza a virus; celastrol; immunomodulation; inflammation; pro-inflammatory cytokine

PMID: 29493374 DOI: 10.1080/08923973.2018.1440591
 
Back
Top Bottom